Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Bendamustine, Obinutuzumab, and Ibrutinib in CLL
NCT02345863Phase 2Completed
- Sponsor
- German CLL Study Group
- Start
- Jan 2015
- Primary completion
- Aug 2016
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib, obinutuzumab in chronic lymphocytic leukemia (CLL), sponsored by German CLL Study Group. Started Jan 2015; status: completed.
02
Drugs
ibrutinibobinutuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02345863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02345863.